Dec 04, 2023 7:00am EST Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
Nov 21, 2023 1:53pm EST Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
Nov 21, 2023 7:00am EST Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
Nov 01, 2023 7:00am EDT Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
Oct 30, 2023 7:00am EDT Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
Oct 26, 2023 7:00am EDT Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
Oct 09, 2023 7:00am EDT Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
Sep 27, 2023 7:00am EDT Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
Sep 07, 2023 7:00am EDT Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
